Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.
This study collected patients used standard neoadjuvant therapy (TCbHP/THP/EC-THP/AC-THP) among stage II-III HR+/HER2+ early breast cancer, and to describe patient clinical characteristics and clinical outcomes of them in real world settings.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Stage II-III HR+/HER2+ Early Breast Cancer | Stage II-III HR+/HER2+ Early Breast Cancer |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Standard Therapy | Drug | Standard Therapy, including TCbHP, THP, EC-THP, AC-THP |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total pathological complete response (tpCR) | tpCR is defined as the absence of residual invasive cancer on resected breast specimen and the sampled regional lymph nodes as shown by hematoxylin-eosin staining after completion of the neoadjuvant treatment. | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Best overall response rate (BORR) [ Time Frame: During neoadjuvant treatment | The proportion of patients who respond to the treatment at any study time point | through study completion, an average of 1 year |
| Residual cancer burden (RCB) |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival (OS) | It refers to the length of time from the start of treatment to the death of the patient. | Within 5 years after surgery |
| Disease-free survival (DFS) | It refers to the length of time from the start of medication after enrollment to the death of the patient because of the recurrence, distant metastasis of the disease, invasive contralateral breast cancer, or any other cause. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients diagnosed with stage II-III HR+/HER2+ early breast cancer.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nan Niu, MD | Contact | +8618940256668 | niunannancy@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Caigang Liu, PHD | Shengjing Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shengjing Hospital of China Medical University | Recruiting | Shenyang | Liaoning | 110004 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
Not provided
Not provided
Not provided
RCB score is obtained according to pathological evaluation after completion of neoadjuvant treatment and surgery
| through study completion, an average of 1 year |
| Within 5 years after surgery |
| D017437 |
| Skin and Connective Tissue Diseases |